---
title: "Rexulti (brexpiprazole), all indications: Specific populations questions"
description: "Specific populations questions on Rexulti (brexpiprazole) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: How is Rexulti dosed in CYP2D6 poor metabolizers? Can Rexulti be used during pregnancy? Can Rexulti be used while breastfeeding? Does Rexulti dosing differ by sex, race, or smoking status? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/rexulti/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole), all indications: Specific populations questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)

## Specific populations

<a id="rexulti-cyp2d6-poor-metabolizers"></a>

### How is Rexulti dosed in CYP2D6 poor metabolizers?

> “Dosage adjustment is recommended in known CYP2D6 poor metabolizers because these patients have higher 
> brexpiprazole concentrations than normal metabolizers of CYP2D6. Approximately 8% of Caucasians and 3 to 
> 8% of Black/African Americans cannot metabolize CYP2D6 substrates and are classified as poor metabolizers 
> [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

> “CYP2D6 poor metabolizers 
> Administer half of the recommended 
> dosage.”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

Note: The second passage is the CYP2D6 poor metabolizer row of Table 1 in Dosage and Administration.

<a id="rexulti-sex-race-smoking"></a>

### Does Rexulti dosing differ by sex, race, or smoking status?

> “The recommended dosage for REXULTI is the same in males and females, in different racial groups, and in 
> smokers and nonsmokers [see Clinical Pharmacology (12.3)].”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

## Pregnancy and breastfeeding

<a id="rexulti-pregnancy"></a>

### Can Rexulti be used during pregnancy?

> “There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to REXULTI 
> during pregnancy. For more information contact the National Pregnancy Registry for Psychiatric Medications at 
> 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.”

Source: [REXULTI: Prescribing information, page 21, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=21)

> “Adequate and well-controlled studies have not been conducted with REXULTI in pregnant women to inform 
> drug-associated risks. However, neonates whose mothers are exposed to antipsychotic drugs, like REXULTI, 
> during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. In animal 
> reproduction studies, no teratogenicity was observed with oral administration of brexpiprazole to pregnant rats 
> and rabbits during organogenesis at doses up to 73 and 146 times, respectively, of maximum recommended 
> human dose (MRHD) of 4 mg/day on a mg/m<sup>2</sup> basis. However, when pregnant rats were administered 
> brexpiprazole during the period of organogenesis through lactation, the number of perinatal deaths of pups 
> was increased at 73 times the MRHD [see Data]. The background risk of major birth defects and miscarriage 
> for the indicated population(s) is unknown. In the U.S. general population, the estimated background risk of 
> major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.”

Source: [REXULTI: Prescribing information, page 21, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=21)

> “Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, 
> respiratory distress and feeding disorder, have been reported in neonates whose mothers were exposed to 
> antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some 
> neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. 
> Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.”

Source: [REXULTI: Prescribing information, page 21, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=21)

<a id="rexulti-breastfeeding"></a>

### Can Rexulti be used while breastfeeding?

> “Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects 
> of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is 
> present in rat milk. The development and health benefits of breastfeeding should be considered along with the 
> mother’s clinical need for REXULTI and any potential adverse effects on the breastfed infant from REXULTI or 
> from the underlying maternal condition.”

Source: [REXULTI: Prescribing information, page 22, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=22)

## Related pages
- [Medical information: Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti)
- [Indication](https://www.evicenter.com/medical-information/rexulti/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rexulti/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/rexulti/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rexulti/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti/access-and-coverage)
